Serum Institute of India (SII) has received an emergency use authorisation (EUA) grant recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) for its Covid-19 vaccine, Covovax, for people aged 12 to 17 years.

The recommendation comes after the panel held a meeting for Covid-19 associated proposals, ANI reported. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The vaccine is produced by the transfer of technology from Novavax. 

In December last year, the DCGI had granted approval to the vaccine for restricted use in an emergency situation for adults.

However, the final approval for emergency use authorisation from DCGI is still awaited.

If DCGI grants the EUA, Covovax will become the fourth vaccine indicated for usage in individuals aged 12 to 17 years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The news agency noted that the vaccine is currently not included in the inoculation drive being carried out in the country to date.

Covovax has also obtained an emergency use listing from the World Health Organization (WHO) and conditional marketing approval from the European Medicines Agency (EMA). 

The company also submitted the results from the Phase III trials on the analysis of the booster dose of the vaccine.

Furthermore, SII obtained permission from the SEC to carry out a Phase III clinical trial of a booster shot of the vaccine in adult subjects, PTI reported quoting official sources.

In February, the company had submitted an application seeking the DCGI approval to carry out the observer-blind, randomised, controlled Phase III trial.

This trial will assess the safety and immunogenicity of the booster vaccine in adults who already received Covid-19 vaccines, Covishield or Covaxin, a minimum of three months ago.

In January, Novavax and SII submitted an application seeking EUA from the South African Health Products Regulatory Agency (SAHPRA) for the former’s Covid-19 vaccine candidate, NVX-CoV2373.